TWI629988B - Skin external composition containing ginsenoside y - Google Patents

Abstract

The present invention relates to a ginsenoside Y-containing external preparation composition, and more specifically, to a ginsenoside Y-containing, through its excellent antioxidant power, it can not only provide skin moisturizing power improvement effect, anti-inflammatory effect , Skin effect improvement effect such as acne and atopic symptoms, whitening effect, sebum adjustment effect, pore contraction effect, improvement of blood color improvement through blood circulation, etc. It also provides anti-dandruff effect and promotes hair Composition for improving scalp and hair condition, such as growth effect and gray hair prevention effect.

Description

Composition for external use on skin containing ginsenoside Y

The present invention relates to a ginsenoside Y-containing external preparation composition, and more specifically, to a ginsenoside Y-containing, through its excellent antioxidant power, it can not only provide skin moisturizing power improvement effect, anti-inflammatory effect Skin condition improvement effects such as acne and atopy symptoms, whitening effect, sebum conditioning effect, pore contraction effect, improvement of blood color improvement through blood circulation, etc., and overall anti-dandruff effect A composition for improving the scalp and hair condition of hair growth promotion effect and gray hair prevention effect.

Human skin is the first protective film of the human body. It plays a role in protecting the organs of the body during the stimulation of external environments such as temperature and humidity changes, ultraviolet rays, and harmful substances. With the increase of age, it undergoes various internal and external Causes change. That is, in terms of internal factors, the secretion of various hormones used to regulate metabolism is reduced, the function of immune cells and cell activity are reduced, resulting in a decrease in the biosynthesis of immune proteins and body structural proteins required by the human body; in terms of external factors Due to the destruction of the ozone layer, the amount of ultraviolet rays reaching the surface of the sun's rays has increased, and as environmental pollution has gradually intensified, free radicals and active oxygen have increased, resulting in reduced skin thickness, increased wrinkles, and reduced elasticity. Cause skin The complexion becomes dull, skin problems often occur, melasma and freckles and age spots are increased, the complexion becomes darker, the complexion becomes darker, etc., resulting in various changes.

In order to prevent changes in the skin state caused by internal and external causes of this kind of skin and to maintain a healthy skin state, bioactive substances extracted from various known animals, plants, microorganisms, etc. are added to cosmetics and used. Improve skin condition. In particular, research and development of cosmetics using ginseng (Panax ginseng C.A Meyer) ingredients have been carried out many times. The efficacy of ginseng on the skin has long been recognized and widely used in cosmetic compositions. Root or leaf extracts of ginseng, ginsenoside, ginsenosides (aglycon), and ginseng polysaccharides have been used in cosmetics. . However, such cosmetics containing ginseng extracts, extracts, polysaccharides, etc., contain extremely small amounts of active substances, and therefore have the following disadvantages compared to other raw materials: their effects are not significantly superior.

In response, the present inventors discovered that ginsenoside Y contained in ginseng can not only provide whitening and moisturizing improvement effects, but also improve the effects of acne and skin problems, specific atopy symptoms, and improve skin color. Skin condition improvement effects such as effects, sebum regulation, pore contraction effects, etc., can also provide scalp and hair condition improvement effects such as anti-dandruff, promote hair growth, and prevent gray hair, etc., thus completing the present invention.

Therefore, an object of the present invention is to provide a skin external preparation composition capable of improving the overall skin condition by containing ginsenoside Y.

To achieve the above object, the present invention provides a skin external preparation composition containing ginsenoside Y as an active ingredient.

The present invention also provides a whitening skin external preparation composition containing ginsenoside Y as an active ingredient.

The present invention also provides a moisturizing skin external preparation composition containing ginsenoside Y as an active ingredient.

The present invention also provides a skin external preparation composition for improving acne containing ginsenoside Y as an active ingredient.

The present invention also provides a skin external preparation composition for improving atopic symptoms including ginsenoside Y as an active ingredient.

The present invention also provides a skin external preparation composition for improving color and skin tone containing ginsenoside Y as an active ingredient.

The present invention also provides a skin external preparation composition for pore shrinkage containing ginsenoside Y as an active ingredient.

The present invention also provides a skin external preparation composition for regulating sebum, containing ginsenoside Y as an active ingredient.

The present invention also provides an antidandruff skin external preparation composition containing ginsenoside Y as an active ingredient.

In addition, the present invention provides a hair growth promoting skin composition containing ginsenoside Y as an active ingredient.

The present invention also provides a skin external preparation composition for preventing white hair containing ginsenoside Y as an active ingredient.

The present invention also provides a skin external preparation composition using ginsenoside Y as a natural preservative.

The composition of the present invention contains ginsenoside Y, and through its excellent antioxidant power, it can not only provide skin moisturizing effect improving effect, anti-inflammatory effect, acne and atopic symptoms, and other skin problem improving effects, whitening Overall skin condition improvement effects such as effects, sebum conditioning effects, pore contraction effects, improved color through blood circulation improvement, etc. It also provides anti-dandruff effects, hair growth promotion effects, and white hair prevention effects such as scalp and hair condition improvement effects .

The composition according to the present invention contains ginsenoside Y as an active ingredient. In particular, the above-mentioned ginsenoside Y can be extracted from ginseng.

Ginsenoside Y used in the present invention has a structure of the following Chemical Formula 1.

Ginseng belongs to the genus Ginseng of the family Araliace, and is a herbaceous plant that perennial semi-shade ground perennial grass. It is produced in South Korea, China, Japan, and the United States. The main production areas are East Asia; 85-140 degrees east longitude, 22-49 degrees north latitude, North America; 70-97 degrees west longitude, 34-47 degrees north latitude. In this way, there are differences in the composition of ginseng produced around the world. Among them, Korean ginseng contains most of the saponin of ginsenoside (Ginsenoside) which exhibits various physiological and pharmacological effects of ginseng. About 34 kinds of ginsenosides have been isolated so far, and each has different medicinal effects according to the type of sugar bound to aglycon, or the number of sugars bound or the binding position. According to the structural characteristics, it can be divided into ginsengdiol system, ginsenotriol system and oleanane system. In addition, the fragrant components containing ginseng are panacen, polyacetylene, polyphenol, flavonoid, and vitamins.

Ginseng has been recognized for its efficacy in Korea since ancient times, and has been used in the treatment of various diseases. Treatment. Ginseng has been known to have physical strength improvement, metabolism improvement, stress relief, diabetes treatment, respiratory disease improvement, digestive organ improvement, and anti-cancer effects in Korean efficacy. In recent research, ginseng has reported anti-complement activity, anti-ulcer effect, Immune enhancement, anti-cancer effect and hypoglycemic effect. The following studies have been published on skin effects and anti-inflammatory effects (Korean J. Dermatol. 18 (1): 39-42 (1980), Korean J. Dermatol. 14 (4): 335-339 (1976)), Hyperkeratosis (Korean J. Dermatol. 28 (4): 434-440 (1990)), prevention and treatment of acne (Korean J. Dermatol. 30 (1): 27-33 (1992), Korean J. Dermatol. 28 (4): 434-440 (1990)), antioxidant effect (Proceedings of the 2nd international ginseng symposium 13-17 (1978)), elasticity and water and sex (Hydration) increase (Fitoterapia 57 (1): 15-28 (1986), Fitoterapia 57 (4) 217-222 (1986)), wound healing (Brit. J. Pharmacol. 125: 255-262 (1998), Arch.pharm.res .25 (1): 71-76 (2002)), collagen degradation inhibition (Mol. Cells 9 (5): 476-483 (1999)), whitening effect (Journal of the society of cosmetic scientists of korea 27 (2 ): 45-56 (2001)) and so on.

The ginsenoside Y of the present invention can be extracted from plants, can also be synthesized and used in accordance with the methods disclosed in the art, and commercially available ginsenoside Y can also be used. Taking into account the technical level in the field, it will be apparent to those having ordinary knowledge in the art that the ginsenoside Y exhibits skin and hair among the derivatives obtained by the addition or replacement reaction of replacements commonly performed in the field. Derivatives with improvement effects and antiseptic effects are also included in the scope of the present invention.

The ginsenoside Y used in the present invention is particularly obtainable from ginseng extracts. At this time, the type of ginseng used is not particularly limited, and water ginseng, red ginseng, white ginseng, Taiji ginseng, and tail ginseng can be used. In addition, the above-mentioned ginseng extract includes all extracts obtained by leaching and frying of ginseng, concentrates obtained by re-concentrating part or all of the extract, or preparation by drying the above-mentioned concentrates again The sinking body, decoction, tincture, fluid extract and chemical substances contained in ginseng, which also exert their main effects, also include the plant itself. Extracts can be taken from all parts of ginseng such as stems, roots, leaves, flowers, and fruits. , Not limited to extracts from a specific part. In addition, as a method for extracting ginsenoside Y from a ginseng extract, a public method can be used.

Specifically, after the ginseng extract is extracted from ginseng with water or an organic solvent by a method well known in the art, the above-mentioned ginsenoside Y can be isolated. The organic solvent used in the present invention may be selected from the group consisting of ethanol, methanol, butanol, ether, and acetic acid. Ethyl ester, chloroform, and a mixed solvent of organic solvents and water are preferably one of 80% ethanol. At this time, preferably, the extraction temperature is 10 ° C to 80 ° C, and extraction can be performed for 3 hours to 24 hours. If the above extraction temperature and extraction time are exceeded, the extraction efficiency will decrease or the composition will change.

Preferably, since the content of the ginsenoside Y in the composition of the present invention is 0.001% to 50% by weight, preferably 0.01 to 30% by weight, and more preferably 0.1 to 10% by weight. If the content of the ginsenoside Y is less than 0.001% by weight, the efficacy and effect of the above components are weak; if the content of the above active ingredient exceeds 50% by weight, problems in skin safety or dosage form may occur.

Since ginsenoside Y is an ingredient having excellent antioxidant power, the composition of the present invention containing ginsenoside Y provides excellent antioxidant power.

The composition of the present invention can be used as a composition for whitening, and can provide excellent whitening effect by blocking tyrosinase activity and suppressing melanin production.

The composition of the present invention can be used as a moisturizing skin external preparation composition, which can strengthen the skin barrier function and induce the differentiation of skin keratinocytes. Thereby, it can be effectively used as a composition for external skin preparations, thereby preventing or improving skin dryness, atopic symptoms, contact dermatitis, or scabies caused by incomplete epidermal differentiation.

The composition of the present invention can be used as a skin external preparation composition for improving acne, and has excellent antibacterial effect, especially has outstanding antibacterial effect on acne-causing bacteria, and also provides anti-inflammatory effect.

The composition of the present invention can be used as a skin external preparation composition for improving color and complexion. After being applied to the skin, it expands capillaries and promotes blood circulation. To ensure that the skin smoothly absorbs nutrients, thereby curbing aging, and has an excellent effect on improving the complexion and complexion.

The composition of the present invention can be used as a skin external preparation composition for pore shrinkage, sebum regulation, and improvement of skin problems. After being applied to the skin, by suppressing sebum secreted due to excess, it promotes elimination of active oxygen and collagen Synthesized to shrink the pores, which has the effect of curbing skin problems by reducing the expression of inflammatory factors. In addition, because of its excellent antioxidant power, it can prevent skin irritation.

The composition of the present invention can be used as an anti-dandruff skin external preparation composition, which can effectively excrete toxins accumulated in the hair and scalp, purify the scalp, curb the proliferation and growth of dandruff bacteria, and thus prevent scalp inflammation. In addition, its outstanding anti-oxidant effect in inhibiting the generation and action of active oxygen can provide the effect of soothing and strengthening the scalp and strengthening the inherent defense ability.

The composition of the present invention can be used as a skin external preparation composition for promoting hair growth, and has the effect of promoting hair growth and preventing hair loss by promoting the hair cycle from the resting phase to the hair growth phase.

The composition of the present invention can be used as an external skin composition for the prevention of white hair, and can significantly suppress white hair and promote black hair by significantly improving the expression of small eye malformation-related transcription factor (MITF) of melanocytes. It takes place.

In addition, ginsenoside Y used in the skin external preparation composition of the present invention can provide the effect of a natural preservative.

The skin external preparation composition of the present invention described above can be formulated as a cosmetic composition, and can be formulated by containing a medium or mechanism permitted by cosmetic science or dermatology. As all dosage forms suitable for topical application, for example, they can be obtained as solutions, gels, solids, stirred anhydrous products, and dispersed in water. Emulsions, suspensions, microemulsions, microcapsules, microspheres, or ionic (liposomes) and non-ionic vesicular dispersants are provided, or they can be provided as creams, lotions, Available in the form of a lotion, powder, ointment, spray or concealer. Alternatively, it can be used in the form of a foam (foam) or an aerosol composition containing a compressed propellant. These compositions can be prepared according to the usual methods in this field.

In particular, if the external skin composition of the present invention is used as an antidandruff, hair growth promotion or gray hair prevention application, it can be formulated into a composition for scalp and hair, and the dosage form is not particularly limited. The dosage form is conditioner, hair nutrition water, softener, hair cream, shampoo, hair cream, hair cream or scalp hair hair care cream.

The composition according to the present invention may contain a fatty substance, an organic solvent, a dissolving agent, a concentrating agent, a gelling agent, a softener, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, and a surface. Active agents, water, ionic or non-ionic emulsifiers, fillers, chelating agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilicity Or lipophilic active agents, lipid vesicular or adjuvants commonly used in the field of cosmetics or dermatology as any other ingredient commonly used in cosmetics. The amount of the above-mentioned adjuvant is based on the amount usually used in the field of cosmetics or dermatology.

In addition, the composition of the present invention may contain a skin absorption promoting substance in order to increase the skin improving effect.

In the following, test examples and formulation examples will be exemplified to more specifically describe the structure and effects of the present invention. However, these test examples and formulation examples are intended to help understand the present invention. However, the scope and scope of the present invention is not limited to the following examples provided for the purpose of examples.

[Reference Example 1]

Ginsenoside Y, which was used to test the efficacy of the composition of the present invention, was purchased from the AMBO Institute.

[Experimental Example 1] Reduction effect of reactive oxygen species (ROS)

Keratinocytes isolated from human epidermal tissues were placed in a 24-well plate at 5 × 10 ⁴ per well and allowed to adhere for 24 hours. After 16 hours, ginsenoside Y was treated at 1%. At this time, for comparison, the control group was not treated with ginsenoside Y. After 2 hours, after removing the culture medium, put 100 μl of phosphate buffered saline (PBS) in each well. After the keratinocytes were irradiated with ultraviolet rays of 30 mJ / cm ² using a UV B (UVB) lamp (Model: K5T8, UV B 15 W, Sankyo Dennki, Japan), PBS was taken out, and keratinocyte culture solution 200 was added to each well μl . Here, the ginsenoside Y is processed again to quantify the amount of reactive oxygen species that are increased by ultraviolet stimulation in each certain time zone. The amount of ROS was quantified with reference to the method of Tan (Tan et al., 1998, J. Cell Biol. Vol. 141, pp1423-1432). Tan's method is to measure the fluorescence of DCF-DA (dichlorofluorescin diacetate) oxidized by ROS. Table 1 shows the results of the calculation of the ratio of light to the ROS of the control group treated with only the excipient.

From the results in Table 1 above, it can be seen that the ginsenoside Y of the present invention can effectively suppress the generation of known ROS that cause skin cell damage due to ultraviolet rays. After the ultraviolet rays are stimulated, the amount of ROS can be irradiated without ultraviolet rays. The above levels can suppress the production of ROS, so that it can be known that its anti-oxidant effect is very good. Therefore, it was confirmed that the ginsenoside Y of the present invention can prevent the enlargement of pores by inhibiting oxidation and preventing aging, and can improve skin problems by preventing the generation of skin irritation.

[Test Example 2] Tyrosinase inhibitory effect

Tyrosinase was extracted from Mushroom, and a tyrosinase prepared by SIGMA was used. First, tyrosine as a matrix was dissolved in distilled water to prepare a 0.3 mg / ml solution, and the solution was added to a test tube in an amount of 1.0 ml, and then 1.0 ml of a potassium-phosphate buffer solution (0.1 mol concentration) was added thereto. , PH 6.8) and 0.7 ml of distilled water.

0.2 ml of a sample solution of ginsenoside Y prepared by mixing at an appropriate concentration was added to the ethanol reaction solution of the present invention and reacted in a constant temperature bath at 37 ° C for 10 minutes. At this time, 0.2 ml of a solvent was used instead of each sample solution as a control group, and ascorbic acid was used as a positive control group. In the reaction solution, a 2500 unit / ml tyrosinase solution was added in 0.1 ml amounts each time, and reacted again in a constant temperature bath at 37 ° C for 10 minutes. The test tube containing the reaction solution was put into ice water, quickly cooled and the reaction was stopped, and the absorbance at a wavelength of 475 nm was measured by a photoelectric spectrum analyzer (Synergy2, BioTek (VT, USA)). The results are shown in the table below. 2. The respective tyrosinase inhibitory effects were calculated by the following formula 1.

[Formula 1] Tyrosinase inhibition rate (%) = 100- (Reaction absorbance of test substance / Reaction absorbance of control group) × 100

From the results in Table 2 above, the inhibition rate of tyrosinase of ginsenoside Y according to the present invention is much higher than that of ascorbic acid, which is known as a tyrosinase inhibitor, and it can be seen that its whitening effect is very excellent.

[Experimental Example 3] Melanogenesis inhibition effect by B16 / F10 melanoma cells

Samples containing 0.1% by weight of each of ginsenoside Y and Kojic acid were used as test substances, and they were added to the culture solution of B16 / F10 melanoma cells (Korean Cell Line Bank) at a predetermined concentration for 3 days. After incubation, the culture medium was removed, the cells were washed with phosphate buffered saline (PBS), and the cells were lysed with 1N sodium hydroxide (NaOH), and the absorbance was measured at 405 nm (Synergy2, BioTek (VT, USA)). The cells to which no test substance was added were used as a control group, and the melanin production inhibition degree of each test substance was measured by comparing the melanin content in the control group. The melanin production inhibition rate was calculated according to Formula 2. The results are shown in Table 3.

[Formula 2] Inhibition rate of melanin production (%) = 100- (absorbance of test substance / absorbance of control group) × 100

[table 3]

From the results in Table 3 above, according to the ginsenoside Y of the present invention, the inhibition rate of melanin production is much higher than that of Kojic acid, which is a well-known melanin production inhibitor, and it can be seen that the whitening effect is very excellent.

[Formulation Example 1 and Comparative Formulation Example 1]

According to the composition of Table 4 below, a nutritional cream (unit: weight%) was prepared by a usual method.

[Test Example 4] Measurement of skin moisturizing power increasing effect

In order to determine the effect of ginsenoside Y on increasing skin moisturizing power, The above-mentioned dosage form example 1 and comparative dosage form example 1 were evaluated as follows.

Twenty adult men and women with dry skin types in the 40-50 age group were divided into two groups with 10 in each group, which corresponded to the two groups of dosage form example 1 and comparative dosage form example 1, respectively. Apply on the subject's face twice a day for 4 weeks. Before the beginning of application, after 1 week of application, after 2 weeks of application, after 4 weeks of application, and after 2 weeks of application stop (6 weeks in total), under constant temperature and humidity conditions (24 ° C, 40% relative humidity), A skin moisture content measuring instrument (Corneometer CM825, C + K Electronic Co., Germany) was used to measure skin moisture content. The results are shown in Table 5 below. The results in Table 5 are based on the skin moisture measurement value measured on the eve of the start of the test, and the percentage increase in the measured value after the prescribed period of treatment.

From Table 5 above, if Comparative Formulation Example 1 is applied, it will show a moisture increase rate of about 30% by the 4th week of application, and the skin moisture content will decrease after application is stopped; on the contrary, If the dosage form example 1 containing ginsenoside Y is applied, the skin moisture increase rate of more than 30% is also shown after the application is stopped. This shows that the composition of the present invention containing ginsenoside Y has excellent skin moisturizing effect.

[Test Example 5] Measurement of keratinocyte differentiation promotion effect

In order to understand the effect of promoting the differentiation of keratinocytes of ginsenoside Y, the amount of keratinocytes produced during the differentiation of keratinocytes was measured by absorbance in the following manner. CE (Cornified Envelop).

First, put human keratinocytes that have been cultured once into a culture bottle and attach them to the bottom. The keratinocytes are separated from the epidermis of the newborn. Then, ginsenoside Y is treated at a concentration of 5 ppm into the culture solution, and then Incubate for 5 days until the cells grow to about 70 ~ 80% of the bottom area. At this time, the low calcium (0.03 mM) treatment group and the high calcium (1.2 mM) treatment group were used as the negative control group and the positive control group, respectively. Next, the above-mentioned cultured cells were extracted, washed with phosphate buffered saline (PBS), and then added with 1 ml of 3% 10mM concentration containing 2% SDS (sodium dodecyl sulfate) and 20 mM DTT (Dithiothreitol). Hydroxymethylaminomethane hydrochloride buffer solution (Tris-HCl, pH 7.4), ultrasonication, boiling, centrifugation, and resuspending the precipitate in 1 ml of phosphate buffer solution (PBS), The absorbance was measured at 340 nm (Synergy2, BioTek (VT, USA)). In addition, the above-mentioned solution after partial ultrasonic treatment was extracted, and its protein content was measured, which was used as a reference when evaluating the degree of cell differentiation. The results are shown in Table 6.

From the results in Table 6 above, it can be seen that if ginsenoside Y is used, the effect of promoting the differentiation of keratinocytes is excellent.

[Test Example 6] Measurement of skin barrier function recovery effect

In order to determine the effect of ginsenoside Y on the restoration of damaged skin barrier function due to skin injury, the following experiments were performed. Peel off with tape (Tape Stripping) method was used to apply skin barrier damage to the upper arms of 10 adult men and women. The two groups of application example 2 and comparative example 2 were prepared by the composition of Table 7 below, respectively, by Vapometer (Delfin, Finland). ) To determine and compare the degree of recovery of transepidermal water loss rate (TWEL), once a day for 7 consecutive days. Among them, Comparative Formulation Example 2 is used as a negative control group, and it is a vehicle. The test results are shown in Table 8 below. The results in Table 8 are based on a 100% comparison of treatment differences before and after barrier damage.

From the results in Table 8 above, if the comparative formulation example 2 that does not contain ginsenoside Y is treated, the transepidermal water loss rate gradually increases over time; on the contrary, if the dosage form example 2 that contains ginsenoside Y is treated, The transepidermal water loss rate quickly returns to normal, and barrier damage is restored.

[Test Example 7] Effect of improving color

In order to evaluate the skin blood circulation promoting effect of the cosmetic composition according to the present invention, blood on the skin was measured by a Laser Doppler Perfusion Imager (periscan PIM II, Perimed (stochholm, Sweden)). Degree of fluid circulation. Laser Doppler blood flow imager is a commonly known instrument for measuring blood circulation in the skin. It is a currently used instrument that can not only measure the speed and amount of blood in the capillaries of the skin, It can also measure the flow in small arteries and veins, which is a very sensitive device.

After washing the face with soap in a constant temperature and humidity room, relax for 30 minutes, and measure the initial value with a laser Doppler blood flow imager. First, for 30 women who usually have cold hands and feet, the initial blood flow of the lower part of their forehead is measured by a laser Doppler blood flow imager. Next, the subjects were arranged to use the above-mentioned dosage form example 1 and the comparative dosage form example 1 within a period of one week, and compared the measured blood flow with the above-mentioned initial measurement value. The results (changes in skin blood flow) are shown in Table 9 below.

From the results in Table 9 above, the cosmetic composition according to the present invention significantly increased skin blood flow compared to Comparative Formulation Example 1 which did not contain ginsenoside Y, and it was found that the appearance of the complexion was promoted by such blood circulation promotion. Improved. In summary, this result indicates that the ginsenoside Y-containing cosmetic composition according to the present invention can contribute to effectively transmitting the nutrients of the skin, suppressing and delaying skin aging.

[Test Example 8] Skin color improvement effect

In order to understand the skin color improvement effect of the above formulation example 1 and comparative formulation example 1, 30 subjects were arranged to use it separately (1 time / day for 1 week), with Facial Stage DM-3 (Moritex, Japan) equipment to evaluate skin tone improvement. Regarding the skin color improvement rate, the skin lightness and color measurement values were measured and the change values were used as the skin color improvement rate. The results are shown in Table 10 below. The larger the brightness and color change values, the higher the improvement in skin tone.

From the results in Table 10 above, it can be seen that Comparative Formulation Example 1 which does not contain ginsenoside Y according to the present invention does not show significant skin tone improvement effect; on the contrary, Formulation Example 1 which contains ginsenoside Y as an active ingredient Compared with the skin tone before use, the skin tone after use is greatly improved.

[Test Example 9] Pore shrinking effect

1. Pore shrinking effect by promoting collagen biosynthesis

The collagen biosynthesis promoting effect of ginsenoside Y according to the present invention was measured by comparison with TGF-β. First, fibroblasts (fibroblast) at 10 ⁵ per well of embodiment seeded (seeding of) in 24-well (Well), its culture was grown until about 90%. After culturing them in serum-free Dulbecco's modified Eagle medium for 24 hours, the ginsenoside Y and TGF-β of the present invention dissolved in serum-free medium were treated at 10 ng / ml, respectively, and cultured in a carbon dioxide medium. 24 hours. The supernatant was removed, and the increase or decrease of the collagen (procollagen) was checked by a collagen prototype (I) ELISA kit (procollagen type (I); # MK101, TAKARA (Shiga, Japan)). The results are shown in Table 11. The collagen synthesis performance is shown based on the non-treated group 100.

As can be seen from the results in Table 11 above, the ginsenoside Y according to the present invention exhibits superiority to a degree higher than TGF-β as a positive control group. Therefore, it is known that the ginsenoside Y according to the present invention can increase the amount of collagen produced around the pores, thereby reducing the enlarged pores.

2. Pore shrinking effect

In order to understand the pore shrinkage effect of Formulation Example 1 and Comparative Formulation Example 1, the evaluation was performed in the following manner. Twenty males and females with enlarged pores were selected and divided into two groups of 10 each. The members of each group applied the nutrition cream of Formulation Example 1 and Comparative Formulation Example 1 on the face for 4 weeks each day. Regarding the judgment of the effect of pore shrinkage, the photos were taken by experts before and 4 weeks after the experiment, and evaluated visually by experts. The results are shown in Table 12 below (evaluation level: 0-no shrinkage was seen; 5- drastically shrinkage).

From the results in Table 12 above, it can be seen that Comparative Formulation Example 1 does not have a pore shrinkage effect, while Formulation Example 1 exhibits a significant pore shrinkage effect that can be seen with the naked eye. From this, it can be known that according to the ginsenoside Y of the present invention, The effect of reducing pore size is excellent.

[Test Example 10] Inhibitory effect on sebum secretion

Skin over-secretion inhibitory effect by inhibition of 1.5α-reductase activity

In order to confirm the 5α-reductase activity inhibitory effect, the ratio of conversion from [ ¹⁴ C] testosterone to [ ¹⁴ C] dihydrotestosterone (DHT: dihydrotestosterone) in HEK293-5αR2 cells was measured. P3 x FLAG-CMV-5αR2 was transfected into HEK293 cells, placed in a 24-well plate at 2.5 x 105 cells per well, and cultured (Park et al., 2003, JDS.Vol. 31, pp. 191- 98). The next day, it was replaced with a new medium with enzyme substrate and inhibitor. As the substrate of the culture medium, 0.05 μCi [ ¹⁴ C] testosterone (Amersham Pharmacia biotech, UK) was used.

In order to confirm the degree of inhibition of 5α-reductase activity, ginsenoside Y was added and cultured in a 5% carbon dioxide incubator at 37 ° C for 2 hours. At this time, the group without adding ginsenoside Y was used as a negative control group, and the group containing finasteride was used as a positive control group. Then, the culture medium was collected, and the steroid was extracted with 800 μl of ethyl acetate. The upper organic solvent layer was separated and dried, and the remaining residue was dissolved again with 50 μl of ethyl acetate, and was dissolved in a silicone plastic sheet silicon F 60 F254) was developed using ethyl acetate-hexane (1: 1) as a solvent.

After drying the plastic sample in the air, use a bathing system to determine the amount of isotopic elements. Put the dried plastic piece together with the X-ray film into the bath cassette. After 1 week, measure the testosterone and The isotopic content of dihydrotestosterone was calculated based on the following formulas 3 and 4, respectively, and the conversion and inhibition rates were calculated. The results are shown in Table 13 below.

[Formula 3]

Conversion rate (%) = radioactive energy in the DHT area / total radioactive energy × 100

[Formula 4] Inhibition rate (%) = (conversion rate of control group-conversion rate of test substance) / conversion rate of control group × 100

From the results in Table 13 above, it can be seen that ginsenoside Y effectively inhibits the activity of 5α-reductase, which converts testosterone to dihydrotestosterone, combines it with water-soluble proteins in the cytoplasm, enters the nucleus and Activates sebaceous gland cells, promotes differentiation, and acts as a super-secretory sebum in the sebaceous glands. Based on this, it is known that ginsenoside Y blocks the conversion from testosterone to dihydrotestosterone, which shows a higher effect than that used to inhibit the activity of 5α-reductase. Nastelier has more excellent suppression effect. Therefore, it is known that ginsenoside Y inhibits the excessive secretion of sebum by effectively inhibiting the activity of 5α-reductase.

2. Sebum secretion inhibitory effect

In order to understand the effect of suppressing sebum secretion of the above-mentioned formulation example 1 and comparative formulation example 1, the evaluation was performed in the following manner. A total of 30 male and female subjects who were considered to have high sebum secretion were selected, and the nutrient cream of Formulation Example 1 and Comparative Formulation Example 1 was applied to the designated area and applied for 4 consecutive weeks each day. Regarding the determination of the effect of sebum reduction, the average sebum reduction rate (%) after 2 weeks and 4 weeks was measured by a sebum volume measuring instrument (Sebumeter SM810, C + K Electronic Co., Germany), and the results are shown in Table 14 below.

From the results in Table 14 above, it can be seen that the dosage form example 1 containing the ginsenoside Y of the present invention as an active ingredient can effectively inhibit the excessive secretion of sebum compared to the comparative dosage form example 1 which does not contain it.

[Formulation example 3 and comparative formulation examples 3 to 4]

Formulation example 3 and comparative formulation examples 3 to 4 were prepared based on the components and contents (% by weight) shown in Table 15 below. Specifically, ginsenoside Y is blended in Formulation Example 3, and Comparative Formulation Example 3 does not contain effective ingredients for improving acne skin at all. Comparative Formulation Example 4 is a standard substance related to antibacterial efficacy, and it is mostly used for acne treatment Erythromycin.

The preparation methods of Formulation Example 3 and Comparative Formulation Examples 3 to 4 are as follows. The components of A in the following Table 15 are completely dissolved, and the components of B are completely dissolved in a separate dissolution tank. B is added to A and mixed and dissolved. Among them, the component C was added according to the mixing ratio shown in Table 15, and after homogeneous mixing, it was filtered to prepare the composition.

[Experimental Example 11] Antibacterial Test on Acne

Each make-up prepared by the composition of dosage form example 3 and comparative dosage form examples 3 to 4 The product composition was subjected to an antibacterial test on Propionibacterium acnes (P.acnes) (ATCC 6919: medium-BHI medium (broth)), which is an acne-producing strain.

The acne-related antibacterial test method is shown below.

(1) Preparation of test bacteria liquid

Propionibacterium acnes uses a culture medium inoculated in BHI medium and anaerobic cultured.

(2) Preparation of diluted solution

0.15 ml of the test bacterial solution was added to 15 ml of BHI medium (pH 6.8) or LB medium (pH 4.5), mixed uniformly, and used as a diluted solution.

(3) Sample preparation

The cosmetic composition stock solutions prepared in Formulation Example 3 and Comparative Formulation Examples 3 to 4 were directly used as samples.

(4) Antibacterial test

1) In a 96-well cell culture tube (96 well plate), line 1, place the sample at the initial concentration, and use it as a diluted solution. Add 200 μl as the unit.

2) After uniformly mixing the mixed solution in line 1 and taking 100 μl and placing it in line 2, uniformly mixing, extracting 100 μl again and putting it in line 3, and carry out double dilution.

3) After performing incubation for 24 hours and 48 hours at 32 ° C, the proliferation of bacteria is judged by the degree of suspension, and the minimum concentration without bacteria proliferation is taken as the minimum inhibitory concentration (MIC, Minimum Inhibitory Concentration) value. If the mixed solution is opaque and it is difficult to judge the proliferation of the bacteria, it is confirmed by microscopic observation.

The results of the acne-related antibacterial test are shown in Table 16. The minimum inhibitory concentration is marked as the concentration of the active ingredient contained in the dosage form.

The lower the ppm concentration of the lowest inhibitory concentration, the more effective it can be in acne-related antibacterial properties. Formulation Example 3 has a significantly higher ppm concentration than Comparative Formulation Example 4 using erythromycin, which is a well-known acne treatment. It can be seen from this that the composition containing ginsenoside Y has a significantly excellent antibacterial effect on the test bacteria.

[Experimental Example 12] Lipogenesis inhibition test

3T3-L1 cells of mouse fibroblast cell line were attached to Dürr containing 10% fetal bovine serum (FBS) at 1 × 10 ⁵ cells / well. A 6-well culture plate of Dulbecco's modified eagle's medium (GIBCO BRL, Life Technologes). After 2 days, the medium was replaced with a new Dulberco modified Igel medium (containing 10% FBS), and the culture was continued for 2 days. Then, the above-mentioned cells that were cultured were differentiated in a Dulberco's modified Igel medium (containing 10% FBS) containing 1 μg / ml insulin, 0.5 mM IBMX, and 0.25 μM dexamethasone. Induction and treatment of ginsenoside Y and caffeine 50 μM, after 2 days of treatment, it was replaced again with Dulberco's modified Eagle's medium containing insulin, and culture was continued for 5 days. After 5 days, the medium was replaced with normal medium (Durberco's modified Eagle's medium containing 10% FBS), and cultured while observing, until the above cells changed into morphologically fat cells.

In order to evaluate the inhibitory effect of ginsenoside Y on fat accumulation in adipocytes, Sudan III staining (S4136, sigma-aldrich) was performed on the differentiated 3T3-L1 adipocytes in the above process. Adipocytes were fixed in phosphate buffered saline with 4% paraformaldehyde (pH 7.2) at room temperature, washed with phosphate buffered saline (PBS), and stained with Sudan III. Take pictures and Make a visual comparison. The control group only used the medium without adding the test substance or the comparative substance. As the other comparison group, the caffeine was treated at 50 μM. Regarding the degree of fat accumulation inhibition, the degree of staining is classified by dividing the degree of staining into +++, ++, +, and-. In this case, the closer to +++, the higher the degree of staining. The results are shown in Table 17 below.

As can be seen from the results in Table 17 above, according to the ginsenoside Y of the present invention, not only the amount of fat accumulated in fat cells is small, but also it has better lipid synthesis than caffeine, which is known as a lipid synthesis inhibitor. Inhibitory effect. Therefore, by inhibiting lipid synthesis and reducing sebum, the generation of acne can be suppressed.

[Test Example 13] Tests on improvement of acne, reduction of sebum secretion, and presence or absence of stimulation

Thirty subjects with acne were divided into three groups in a manner of ten in each group, and the subjects in each group were arranged to use the cosmetic composition prepared in the above formulation example 3 and comparative formulation examples 3 to 4, respectively. The acne improvement scale is set from 1 to 5 points, with 1 being "not "Yes", 3 points are "fair", and 5 points are "very yes." The experimental results are marked by the average scores of the 10 participants in Table 18 below.

The period of acne disappearance is based on the number of days when the acne disappearance is read. The occurrence of acne recurrence is based on the result after one month. Sebum secretion reduction scale is set to 1 to 5 points, 1 is "not", 3 is "fair", and 5 is "very yes". The experimental results are marked by the average scores of the 10 participants in Table 18 below. The presence or absence of skin irritation is indicated by (the number of people who show a stimulus response) / (the total number of subjects).

As can be seen from the results in Table 18 above, compared with Comparative Formulation Example 3, Formulation Example 3 had no recurrence of acne, and had an excellent effect on improving acne as a whole. In addition, in Comparative Formulation Example 4 containing an antibacterial standard substance, although it shows an acne-improving effect, it shows strong skin irritation during use, which is not suitable for long-term use. Non-irritating, showing long-term use.

[Test Example 14] IL-8 Production Inhibition Effect

One day before the start of the experiment, normal human skin keratinocytes (NHEK, purchased from: Lonza) were dispersed in 96-well plates at 5 x ^{10 4} cells / well, and then incubated at 37 ° C and 5% carbon dioxide incubator (incubator). ) For 24 hours. After 24 hours, the cells were washed twice with sulfate buffer (PBS) and replaced with serum-free KBM (serum free keratinocyte basement media). To each well, ginsenoside Y was treated at the concentration shown in Table 19 below. After 30 minutes of reaction, PGSA (10 μg / ml), PGSA (50 μg / ml), PGSA (50 μg / ml) + LPS (1 μg / ml) were processed. . Among them, PGSA (peptidoglycan from S. aureus) is a peptidoglycan extracted from Staphylococcus. It is the main component of the cell wall of Gram-positive (+) bacteria. The cell membrane component of bacteria can cause inflammation, especially According to reports, about 90% of patients with specific responsiveness have secondary infections caused by staphylococci. Endotoxin (LPS, lypopolysaccaride) is the main component of the cell membrane of Gram-negative (-) bacteria, and it is the main cause of inflammation.

After incubating in a 5% carbon dioxide (CO2) incubator at 37 ° C for 24 hours, the culture fluid was extracted, and an enzyme-linked immunosorbent assay (ELISA) was performed against Interleukin-8 (IL-8). The results are shown in Table 19. The enzyme-linked immunosorbent assay (ELISA) uses an experimental method of a manufacturing company (BD science).

From the results in Table 19 above, it can be seen that ginsenoside Y can significantly reduce and inhibit the secretion of IL-8 increased by PGSA and LPS. Therefore, the skin external preparation composition of the present invention can provide an excellent anti-inflammatory effect by significantly reducing the secretion of IL-8 increased by PGSA and LPS.

[Test Example 15] Evaluation of Antipruritic

One day before the start of the experiment, keratinocytes (cell line name: HaCaT source: ATCC) were dispersed in 96-well plates at ⁴ × ^{10 4} cells / well, and cultured at 37 ° C. in a 5% carbon dioxide incubator for 24 hours. After 24 hours, the 96-well plate was washed twice with Hanks' Balanced Salt solution buffer, and then the reaction buffer (2 μM Fluo-4-AM, 20% pluronic acid, 2.5 mM) was washed. probenecid) cells. The reaction was carried out in a 37 ° C, 5% carbon dioxide incubator for 30 minutes, and then at room temperature for 30 minutes, and then washed twice with Hank's Balanced Salt Solution (HBSS) buffer, and the concentrations (%) were as shown in Table 20 below. Ginsenoside Y treated cells.

After 10 minutes of reaction, 2U / ml trypsin or 5 μM PAR-2 active peptide (SLIGKV) was treated and the intracellular Ca2 + concentration was measured for 80 seconds. For measurement of changes in intracellular Ca2 + concentration, a multifunctional microplate reader 3 (FlexStation3: Molecular Device, USA) was used. After processing the ginsenoside Y and 2U / ml trypsin (Trypsin) or 5 μM PAR-2 active peptide (SLIGKV), measure Flex for 80 seconds, find the difference between the minimum and maximum values obtained, and compare it with 2U / The difference between the minimum value and the maximum value when treated with ml trypsin or 5 μM PAR-2 active peptide (SLIGKV) was compared, and the inhibition rate (%) of intracellular influx of calcium ions is shown in Table 20 below.

From the results in Table 20 above, it can be seen that the amount of calcium ions flowing into the cells of trypsin or PAR-2 active peptide (SLIGKV) decreases with the treatment of ginsenoside Y. By increasing the concentration of ginsenoside Y, it is possible to Significantly reduces the influx of calcium ions.

Therefore, the skin external preparation composition containing the ginsenoside Y of the present invention can provide an excellent antipruritic effect by effectively inhibiting the PAR-2 activity that causes itching.

[Formulation example 4 and comparative formulation example 5]

The composition of Table 21 below was used to prepare a shampoo. Specifically, add surfactant and ethylene glycol distearate to purified water, heat to 80 ° C and dissolve uniformly, stir and gradually reduce the temperature to 40 ° C, add to the above mixture according to After the effective ingredients and preservatives, viscosity modifiers, perfumes, and hair conditioners of the present invention, they are stirred and cooled to room temperature to complete the preparation.

[Test Example 16] Anti-dandruff effect test

Twenty-four males aged 19-35 years with more dandruff were selected. The formula was divided into two groups, and each group was arranged to use the shampoo of Formulation Example 4 and Comparative Formulation Example 5, respectively, and the dandruff reduction rate was measured after 1 month of continuous use.

Before starting the test, use a normal shampoo to shampoo, collect the dandruff accumulated within 2 days after shampooing, measure the weight of the dandruff, and then use the shampoos of Formulation Example 4 and Comparative Formulation Example 5 every two times. Shampoo once a day, collect dandruff accumulated within 2 days after the test is completed, measure the weight of dandruff, and compare the two. At this time, the accumulated dandruff was directly collected from the scalp by the vacuum suction device, and the dandruff reduction rate was obtained according to the following formula 5. The results are shown in Table 22 below.

[Formula 5] Dandruff reduction rate (%) = {dandruff weight before the test (mg)-dandruff weight after one month (mg)} / dandruff weight before the test (mg) × 100

As can be seen from the results in Table 22 above, the dosage form example 4 containing ginsenoside Y exhibited an excellent antidandruff effect.

[Test Example 17] Test for Preventing Scalp Pruritus

24 men and women aged 25 to 45 with severe scalp pruritus were selected Each group was divided into 2 groups by 12 people, and the shampoos of each dosage form example 4 and comparative dosage form example 5 were arranged for continuous use once every 3 days for 2 weeks, and the scalp itching prevention effect was evaluated by the following evaluation criteria The results are shown in Table 23.

[Evaluation Criteria]

Very good -5 points

Excellent -4 points

Average -3 points

Unqualified-2 points

Very unqualified-1 point

From the results in Table 23 above, it can be seen that Formulation Example 4 containing ginsenoside Y exhibits more excellent effects in preventing itching of the scalp.

[Experimental Example 18] Effect of hair follicle hair papilla cell proliferation

Keratin proteins that make up hair are produced by hair root keratinocytes, which are differentiated from hair papilla cells. In order to evaluate the activity of hair papilla cells of the composition, a DP6 (rat immortalized dermal papilla cell) cell line (Wendy Filsell, Journal of Cell Science 107, 1761-1772 (1994)) is used in the present invention. This hair papilla cell line is a cell line obtained by culturing male roots of male PVG rat whiskers by a microdissection method. The cell line is in DMEM (Dulbecco's modified Eagle's medium, Gibco BRL) containing 10% FBS (Fetal bovine serum). , Gaithersburg, MD, USA), cultures maintained at 5% carbon dioxide, 37 ° C Incubate for 24 hours. After DP6 was put into a 96-well plate and cultured in a 37 ° C incubator for 24 hours, the ginsenoside Y was treated at a concentration of 5 ppm, 10 ppm, and 20 ppm, respectively. 24 hours after the drug treatment, the cell proliferation ability was measured using a WST-1 kit (Roche). The results are shown in Table 24 below.

From the results in Table 24 above, it can be seen that when ginsenoside Y is treated, the proliferation of hair papilla cells increases, and a significant increase in this concentration dependence can be confirmed.

[Experimental Example 19] Evaluation of the effect of increasing potassium channel activity

Minoxidil as a hair loss treatment agent is considered to be a potential mitochondrial potassium ion channel opener (K _ATP channel opener), which is a representative drug for androgenic alopecia. In order to evaluate the mechanism of such minoxidil, a test method was used in which tolbutamide (SIGMA AlDRICH, T0891) for blocking mitochondrial potassium ion channels was treated in fibroblasts constituting the dermis of the scalp, and Inhibit cell proliferation, reopen potassium channels and restore cell proliferation.

In order to evaluate the function of the composition as a mitochondrial potassium ion channel opener, a fibroblast cell line NIH3T3 (Mouse embryonic fibroblast cell line) cell line is used in the present invention. This cell line will be a fibroblast cell line isolated from the NIH Swiss mouse embryo using the 3T3 protocol. Natural immortal cell line. The above cell lines were cultured in a Dulberco modified Igel medium (Gibco BRL, Gaithersburg, MD, USA) containing 10% FBS in an incubator maintained at 5% carbon dioxide at 37 ° C for 24 hours. Put NIH3T3 into a 96-well plate, incubate in a 37 ° C incubator for 24 hours, and then process 2.5 mM tolbutamide. After 10 minutes, 10 μM minoxidil and ginsenoside Y as positive control groups were 2.5 ppm Treatment at concentrations of 5 ppm and 10 ppm. After 48 hours of drug treatment, the cell proliferation ability was measured using a WST-1 kit (Roche). The results are shown in Table 25 below.

From the results in Table 25 above, it can be known that if ginsenoside Y is treated, the proliferation of fibroblasts is restored. As the concentration of treated ginsenoside Y increases, its cell proliferation ability also increases. If ginsenoside Y is treated at 10 ppm, Then, the degree of cell proliferation recovery is as high as that in the case of treating minoxidil.

[Test Example 20] Test of melanin production promotion effect of ginsenoside Y

5% fetal calf serum, 100 IU of penicillin G, and 0.2 μM of TPA were added to the RPMI medium, and melan-a was dispersed into a 24-well microtiter plate at 50,000 cells / well. The next day, the dispersed cells were treated with ginsenoside Y as a test substance at a final concentration of 10 ppm or 50 ppm, 0.1% DMSO as a negative control group, and 100 μM IBMX as a positive control group, and cultured at 37 ° C for 3 days . After incubation, use The wells were washed with phosphate buffered saline (PBS), and 1N sodium hydroxide (NaOH) was added in an amount of 100 μl each time to dissolve the melanin in the cells. The absorbance of the dissolved melanin was measured at 405 nm using a microplate reader (Synergy2, BioTek (VT, USA)). The melanin production promoting effect of ginsenoside Y is compared with the control group, and the results are shown in Table 26 below.

As can be seen from the results in Table 26 above, ginsenoside Y promotes melanin synthesis in melanocytes and increases the amount of melanin production, thereby exhibiting an excellent melanin production promotion effect.

[Experimental Example 21] Effect of promoting expression of small eye malformation-related transcription factor (MITF) and tyrosinase in melanocytes of ginsenoside Y

501mel cell lines were dispersed into 6-well microtiter plates at 500,000 cells / well. For each well, 0.1% DMSO was treated as a negative control group, IBMX 100 μM was treated as a positive control group, and The test group treated ginsenoside Y at 10 ppm and cultured at 37 ° C for 24 hours, 48 hours, and 72 hours to obtain protein. The protein thus obtained was subjected to immunoblotting with small eye malformation-related transcription factor (MITF) and tyrosinase antibody. Protein extraction and western blotting typically use standard methods employed by those skilled in the art. After the immunoblot was completed, the results were compared with 100 of the negative control group, and the results are shown in Table 27 below.

From the results in Table 27 above, it can be seen that ginsenoside Y can improve the expression of small eye malformation-related transcription factor (MITF) and tyrosinase protein in melanocytes.

[Experimental Example 22] Evaluation of Antibacterial Effect of Ginsenoside Y

In order to evaluate the antibacterial power of ginsenoside Y, an antibacterial experiment was performed. The specific method is described below.

Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa strains used for the experiments were cultured in Tryptic Soy Broth, and Candida albicans 1. Aspergillus niger strains were cultured in Sabouraud Dextrose Broth. The culture solution was diluted 1/100 (1/10 of Candida albicans strain) to each culture medium and used as a test bacterial solution. Aspergillus niger was used as a test bacterial solution, a spore suspension prepared at 2 × 10 ⁸ cfu / ml.

0.15 ml of the above-mentioned test bacteria solution was added to each 15 ml of the culture medium, and they were uniformly mixed and used as a diluted solution.

16 μl of each sample was placed in row 96 of a 96 well plate (96 well plate), and 184 μl of each diluted solution was placed. Put 100 μl of the diluted solution into each of the remaining wells. After uniformly mixing the mixed solution of line 1 and extracting 100 μl and placing it in line 2, after uniformly mixing, extracting 100 μl again and placing it in line 3, in this way, a 2-fold dilution was performed.

Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were cultured in a thermostatic bath at 32 ° C. Candida albicans and Aspergillus niger were cultured at 25 ° C. Cultivate in a constant temperature bath at ℃.

After 48 hours, the presence or absence of bacterial proliferation and the degree of suspension were confirmed by a microscope, and the minimum inhibitory concentration (MIC) value was determined, and the results are shown in Table 28 below.

From the results in Table 28 above, it can be seen that ginsenoside Y exhibits antibacterial power against various strains, and from this, it can be predicted that ginsenoside Y can function as a natural preservative or antibacterial agent in the composition.

Claims (19)

A skin external preparation composition includes ginsenoside Y as the only active ingredient, and the ginsenoside Y is represented by the following chemical formula 1:

The content of the ginsenoside Y is 0.001% to 50% by weight based on the total weight of the composition. A skin external preparation composition includes ginsenoside Y as the only effective ingredient, wherein the content of the ginsenoside Y is 0.1% to 10% by weight of the total weight of the composition, and the skin external preparation composition has a component selected from the group consisting of At least one cosmetic use for the following purposes: skin whitening, skin moisturization, enhancement of skin barrier function, promotion of skin keratinocyte differentiation, improvement of acne, antibacterial, inhibition of lipid production, improvement of atopic symptoms, improvement of complexion and complexion, skin Shrink pores, regulate sebum secretion, improve skin problems, protect against skin irritation, resist dandruff, promote hair growth, prevent white hair, and provide antiseptic effects. A use of ginsenoside Y to prepare a composition for skin whitening, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for moisturizing skin, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for enhancing skin barrier function, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for inducing skin keratinocyte differentiation, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for improving acne, wherein ginsenoside Y is the only active ingredient therein. The use of ginsenoside Y to prepare antibacterial composition, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for inhibiting lipid production, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for improving atopic symptoms, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for improving color and skin tone, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for shrinking pores, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for regulating sebum secretion, in which ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for improving skin problems, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for preventing skin irritation, in which ginsenoside Y is the only effective ingredient therein. A use of ginsenoside Y to prepare a composition for anti-dandruff, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for promoting hair growth, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y to prepare a composition for preventing occurrence of bleaching, wherein ginsenoside Y is the only active ingredient therein. A use of ginsenoside Y for preparing a composition for a natural preservative for a cosmetic composition, wherein ginsenoside Y is the only preservative component therein.